MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MediWound Ltd. - Ordinary Shares (MDWD)
Last mediwound ltd. - ordinary shares earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mediwound.com/press-releases
Company Research
Source: GlobeNewswire
VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. “We continue to execute across our clinical, commercial, and operational objectives,” said Ofer Gonen, Chief Executive Officer of MediWound. “The VALUE Phase III trial of EscharEx® is actively recruiting patients, and with the addition of Convatec and Essity to our clinical partnerships, we are now collaborating with all re
Show less
Read more
Impact Snapshot
Event Time:
MDWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDWD alerts
High impacting MediWound Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MDWD
News
- MediWound to Report Third Quarter 2025 Financial ResultsGlobeNewswire
- MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®GlobeNewswire
- MediWound (NASDAQ:MDWD) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares [Yahoo! Finance]Yahoo! Finance
- MediWound Announces $30 Million Registered Direct Offering of Ordinary SharesGlobeNewswire
MDWD
Earnings
- 8/14/25 - Miss
MDWD
Sec Filings
- 10/3/25 - Form SCHEDULE
- 9/30/25 - Form 6-K
- 9/30/25 - Form 424B5
- MDWD's page on the SEC website